Agios Pharmaceuticals, Inc. $AGIO Stake Lifted by BNP Paribas Financial Markets

BNP Paribas Financial Markets raised its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 1,551.0% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 242,670 shares of the biopharmaceutical company’s stock after purchasing an additional 227,972 shares during the quarter. BNP Paribas Financial Markets’ holdings in Agios Pharmaceuticals were worth $6,605,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Assetmark Inc. boosted its holdings in Agios Pharmaceuticals by 37.9% during the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 362 shares in the last quarter. NewEdge Advisors LLC acquired a new position in Agios Pharmaceuticals in the 1st quarter worth approximately $40,000. Quantbot Technologies LP acquired a new position in Agios Pharmaceuticals in the 3rd quarter worth approximately $79,000. Eurizon Capital SGR S.p.A. acquired a new position in Agios Pharmaceuticals in the 4th quarter worth approximately $72,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Agios Pharmaceuticals by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,834 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 588 shares during the period.

Insider Transactions at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 3,141 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $109,024.11. Following the completion of the transaction, the chief financial officer owned 54,998 shares of the company’s stock, valued at $1,908,980.58. This represents a 5.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James William Burns sold 3,280 shares of the firm’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total transaction of $113,848.80. Following the transaction, the insider directly owned 49,306 shares of the company’s stock, valued at $1,711,411.26. The trade was a 6.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 12,623 shares of company stock worth $438,144. 5.40% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO opened at $28.14 on Wednesday. The company’s 50 day simple moving average is $29.55 and its 200 day simple moving average is $28.43. Agios Pharmaceuticals, Inc. has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The firm has a market capitalization of $1.67 billion, a P/E ratio of -3.88 and a beta of 0.59.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.81) by $0.12. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%. The company had revenue of $20.75 million for the quarter, compared to the consensus estimate of $13.30 million. The firm’s revenue for the quarter was up 137.7% compared to the same quarter last year. Sell-side analysts expect that Agios Pharmaceuticals, Inc. will post -6.2 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on AGIO shares. Wall Street Zen upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Friday, March 27th. HC Wainwright reduced their price target on Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating for the company in a report on Monday, April 20th. JPMorgan Chase & Co. lifted their price objective on shares of Agios Pharmaceuticals from $31.00 to $36.00 and gave the company a “neutral” rating in a research note on Monday, April 6th. Finally, Citigroup lifted their price objective on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Agios Pharmaceuticals has an average rating of “Hold” and an average target price of $41.44.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.